David L. Szekeres has served on the Sanford Burnham Prebys Board of Trustees since 2019.
He is president of Connect Biopharma, a global, clinical-stage biopharmaceutical company developing innovative therapies that treat inflammatory diseases.
Previously, Szekeres had been executive vice president and chief operating officer of Heron Therapeutics, a San Diego-based biotechnology company developing best-in-class treatments in oncology and pain. Prior to that, he was chief business officer, principal financial officer and general counsel at Regulus Therapeutics; head of Mergers & Acquisitions at Life Technologies Corporation; a corporate attorney at Latham & Watkins; and a senior associate in investment banking at Robertson Stephens.
Szekeres serves as chairman of the board of GRI Bio, a clinical-stage biopharmaceutical company focused on inflammatory and autoimmune disease treatment; and an executive advisory board member at Colossal Biosciences, a biotechnology and genetic engineering company working to genetically resurrect extinct animal species.
He is also a board member of CureMatch, a software company focused on personalized medicine and combination therapy in oncology; and chairman of the board of Animantis, a software company focused on automated, cloud-based, artificial intelligence applications to improve drug discovery and development.
He has a Bachelor of Arts degree in criminology, law and society from the University of California Irvine and a Juris Doctor degree from Duke University School of Law.